Agency Information Collection Activities: Proposed Collection; Comments Requested: Application for Individual Manufacturing Quota for a Basic Class of Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine, 71831-71832 [2012-29213]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 233 / Tuesday, December 4, 2012 / Notices
mstockstill on DSK4VPTVN1PROD with
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’), SGIP
2.0, Inc. (‘‘SGIP 2.0’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing (1) the name and
principal place of business of the
standards development organization
and (2) the nature and scope of its
standards development activities. The
notifications were filed for the purpose
of invoking the Act’s provisions limiting
the recovery of antitrust plaintiffs to
actual damages under specified
circumstances.
Pursuant to Section 6(b) of the Act,
the name and principal place of
business of the standards development
organization is SGIP 2.0, Inc., c/o
Gesmer Updegrove LLP, Boston, MA.
The nature and scope of SGIP 2.0’s
standards development activities are:
SGIP 2.0 is organized exclusively for
charitable, religious, educational,
literary, and scientific purposes, within
the meaning of Section 501(c)(3) of the
Internal Revenue Code of 1986, as
amended (or the corresponding
provision of any subsequent federal tax
law), and the regulations currently or
hereafter promulgated thereunder. In
furtherance of such purposes, SGIP 2.0
is organized and will be operated
primarily to continue the work of the
unincorporated SmartGrid
Interoperability Panel, by supporting the
National Institute of Standards and
Technology in fulfilling its
responsibilities pursuant to the Energy
Independence and Security Act of 2007,
including but not limited to by (a)
providing technical guidance and
coordination to help facilitate standards
development for smart grid
interoperability; (b) identifying and
specifying testing and certification
requirements, including provision of the
underlying rationale to assess
achievement of interoperability using
smart grid standards; (c) informing and
educating smart grid industry
stakeholders regarding smart grid
interoperability and related benefits; (d)
liaising with similar organizations in
other countries to help establish global
smart grid interoperability alignment;
and (e) undertaking such other activities
as may from time to time be appropriate
to further the purposes and achieve the
goals set forth above.
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2012–29266 Filed 12–3–12; 8:45 am]
BILLING CODE P
VerDate Mar<15>2010
17:31 Dec 03, 2012
Jkt 229001
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—3D PDF Consortium, Inc.
Notice is hereby given that, on
November 8, 2012, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. § 4301 et seq. (‘‘the Act’’), 3D
Consortium, Inc. (‘‘3D PDF’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
Boeing Shared Services Group, Seattle,
WA, has been added as a party to this
venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and 3D PDF
intends to file additional written
notifications disclosing all changes in
membership.
On March 27, 2012, 3D PDF filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on April 20, 2012 (77 FR 23754).
The last notification was filed with
the Department on August 20, 2012. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on September 14, 2012 (77 FR
56861).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2012–29269 Filed 12–3–12; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[OMB Number 1117–0006]
Agency Information Collection
Activities: Proposed Collection;
Comments Requested: Application for
Individual Manufacturing Quota for a
Basic Class of Controlled Substance
and for Ephedrine, Pseudoephedrine,
and Phenylpropanolamine
ACTION:
PO 00000
60-Day Notice.
Frm 00060
Fmt 4703
Sfmt 4703
71831
The Department of Justice (DOJ), Drug
Enforcement Administration (DEA), will
be submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies. Comments
are encouraged and will be accepted
until February 4, 2013. This process is
conducted in accordance with 5 CFR
1320.10.
If you have comments, especially on
the estimated public burden or
associated response time, suggestions,
or need a copy of the proposed
information collection instrument with
instructions or additional information,
please contact Cathy Gallagher, Chief,
Liaison and Policy Section, Office of
Diversion Control, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, VA 22152.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of Information Collection
1117–0006
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
Application for Individual
Manufacturing Quota for a Basic Class
of Controlled Substance and for
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine (DEA Form 189).
(3) Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
E:\FR\FM\04DEN1.SGM
04DEN1
71832
Federal Register / Vol. 77, No. 233 / Tuesday, December 4, 2012 / Notices
collection: Form Number: DEA Form
189, Office of Diversion Control, Drug
Enforcement Administration,
Department of Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: Business or other for-profit.
Other: None.
Abstract: 21 U.S.C. 826 and 21 CFR
1303.22 and 1315.22 require that any
person who is registered to manufacture
any basic class of controlled substances
listed in Schedule I or II and who
desires to manufacture a quantity of
such class, or who desires to
manufacture using the List I chemicals
ephedrine, pseudoephedrine, or
phenylpropanolamine, must apply on
DEA Form 189 for a manufacturing
quota for such quantity of such class or
List I chemical.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: DEA estimates that each form
takes 0.5 hours (30 minutes) to
complete. In total, 33 firms submit 641
responses, with each response taking 0.5
hours (30 minutes) to complete. This
results in a total public burden of 320.5
hours annually.
(6) An estimate of the total public
burden (in hours) associated with the
collection: In total, 33 firms submit 641
responses, with each response taking 0.5
hours (30 minutes) to complete. This
results in a total public burden of 320.5
hours annually.
If additional information is required
contact: Jerri Murray, Department
Clearance Officer, Policy and Planning
Staff, Justice Management Division,
Department of Justice, Two Constitution
Square, 145 N Street NE., Suite 3W–
1407B, Washington, DC 20530.
Dated: November 27, 2012.
Jerri Murray,
Department Clearance Officer for PRA,
United States Department of Justice.
[FR Doc. 2012–29213 Filed 12–3–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSK4VPTVN1PROD with
[OMB Number 1117–0008]
Agency Information Collection
Activities: Proposed Collection;
Comments Requested: Application for
Procurement Quota for Controlled
Substances and Ephedrine,
Pseudoephedrine, and
Phenylpropanolamine DEA Form 250
ACTION:
60-Day Notice.
VerDate Mar<15>2010
17:31 Dec 03, 2012
Jkt 229001
The Department of Justice (DOJ), Drug
Enforcement Administration (DEA), will
be submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection is
published to obtain comments from the
public and affected agencies. Comments
are encouraged and will be accepted
until February 4, 2013. This process is
conducted in accordance with 5 CFR
1320.10.
If you have comments, especially on
the estimated public burden or
associated response time, suggestions,
or need a copy of the proposed
information collection instrument with
instructions or additional information,
please contact Cathy Gallagher, Chief,
Liaison and Policy Section, Office of
Diversion Control, Drug Enforcement
Administration, 8701 Morrissette Drive,
Springfield, VA 22152.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses.
Overview of Information Collection
1117–0008
(1) Type of Information Collection:
Extension of a currently approved
collection.
(2) Title of the Form/Collection:
Application for Procurement Quota for
Controlled Substances and Ephedrine,
Pseudoephedrine, and
Phenylpropanolamine (DEA Form 250).
(3) Agency form number, if any, and
the applicable component of the
Department of Justice sponsoring the
collection: Form Number: DEA Form
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
250, Office of Diversion Control, Drug
Enforcement Administration,
Department of Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract:
Primary: Business or other for-profit.
Other: None.
Abstract: 21 U.S.C. 826 and 21 CFR
1303.12 and 1315.32 require that U.S.
companies who desire to use any basic
class of controlled substances listed in
Schedule I or II or the List I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine for purposes of
manufacturing during the next calendar
year shall apply on DEA Form 250 for
procurement quota for such class or List
I chemical.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: DEA estimates that each form
takes 1⁄2 hour to complete. DEA
estimates that 419 individual
respondents will respond to this form.
DEA estimates that 2,716 responses are
received annually.
(6) An estimate of the total public
burden (in hours) associated with the
collection: The total public burden for
this collection is 1,358 hours annually.
If additional information is required
contact: Jerri Murray, Department
Clearance Officer, Policy and Planning
Staff, Justice Management Division,
Department of Justice, Two Constitution
Square, 145 N Street NE., Room 3W–
1407B, Washington, DC 20530.
Dated: November 27, 2012.
Jerri Murray,
Department Clearance Officer for PRA,
United States Department of Justice.
[FR Doc. 2012–29214 Filed 12–3–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Foreign Claims Settlement
Commission
[F.C.S.C. Meeting and Hearing Notice No.
10–12]
Sunshine Act Meeting
The Foreign Claims Settlement
Commission, pursuant to its regulations
(45 CFR 503.25) and the Government in
the Sunshine Act (5 U.S.C. 552b),
hereby gives notice in regard to the
scheduling of open meetings as follows:
Wednesday, December 12, 2012: 9:00
a.m.—Oral hearings on Objection to
Commission’s Proposed Decisions in
Claim No. LIB–II–164; 10:30 a.m.—
Claim Nos. LIB–II–113/LIB–II–117;
11:00 a.m.—Issuance of Proposed
Decision in claims against Libya;
E:\FR\FM\04DEN1.SGM
04DEN1
]]>Agencies
[Federal Register Volume 77, Number 233 (Tuesday, December 4, 2012)]
[Notices]
[Pages 71831-71832]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-29213]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[OMB Number 1117-0006]
Agency Information Collection Activities: Proposed Collection;
Comments Requested: Application for Individual Manufacturing Quota for
a Basic Class of Controlled Substance and for Ephedrine,
Pseudoephedrine, and Phenylpropanolamine
ACTION: 60-Day Notice.
-----------------------------------------------------------------------
The Department of Justice (DOJ), Drug Enforcement Administration
(DEA), will be submitting the following information collection request
to the Office of Management and Budget (OMB) for review and approval in
accordance with the Paperwork Reduction Act of 1995. The proposed
information collection is published to obtain comments from the public
and affected agencies. Comments are encouraged and will be accepted
until February 4, 2013. This process is conducted in accordance with 5
CFR 1320.10.
If you have comments, especially on the estimated public burden or
associated response time, suggestions, or need a copy of the proposed
information collection instrument with instructions or additional
information, please contact Cathy Gallagher, Chief, Liaison and Policy
Section, Office of Diversion Control, Drug Enforcement Administration,
8701 Morrissette Drive, Springfield, VA 22152.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address one or more of the following
four points:
Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
Evaluate the accuracy of the agencies estimate of the
burden of the proposed collection of information, including the
validity of the methodology and assumptions used;
Enhance the quality, utility, and clarity of the
information to be collected; and
Minimize the burden of the collection of information on
those who are to respond, including through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses.
Overview of Information Collection 1117-0006
(1) Type of Information Collection: Extension of a currently
approved collection.
(2) Title of the Form/Collection: Application for Individual
Manufacturing Quota for a Basic Class of Controlled Substance and for
Ephedrine, Pseudoephedrine, and Phenylpropanolamine (DEA Form 189).
(3) Agency form number, if any, and the applicable component of the
Department of Justice sponsoring the
[[Page 71832]]
collection: Form Number: DEA Form 189, Office of Diversion Control,
Drug Enforcement Administration, Department of Justice.
(4) Affected public who will be asked or required to respond, as
well as a brief abstract:
Primary: Business or other for-profit.
Other: None.
Abstract: 21 U.S.C. 826 and 21 CFR 1303.22 and 1315.22 require that
any person who is registered to manufacture any basic class of
controlled substances listed in Schedule I or II and who desires to
manufacture a quantity of such class, or who desires to manufacture
using the List I chemicals ephedrine, pseudoephedrine, or
phenylpropanolamine, must apply on DEA Form 189 for a manufacturing
quota for such quantity of such class or List I chemical.
(5) An estimate of the total number of respondents and the amount
of time estimated for an average respondent to respond: DEA estimates
that each form takes 0.5 hours (30 minutes) to complete. In total, 33
firms submit 641 responses, with each response taking 0.5 hours (30
minutes) to complete. This results in a total public burden of 320.5
hours annually.
(6) An estimate of the total public burden (in hours) associated
with the collection: In total, 33 firms submit 641 responses, with each
response taking 0.5 hours (30 minutes) to complete. This results in a
total public burden of 320.5 hours annually.
If additional information is required contact: Jerri Murray,
Department Clearance Officer, Policy and Planning Staff, Justice
Management Division, Department of Justice, Two Constitution Square,
145 N Street NE., Suite 3W-1407B, Washington, DC 20530.
Dated: November 27, 2012.
Jerri Murray,
Department Clearance Officer for PRA, United States Department of
Justice.
[FR Doc. 2012-29213 Filed 12-3-12; 8:45 am]
BILLING CODE 4410-09-P
